Hearing loss--risk factor for cisplatin ototoxicity? Observations.
Ototoxicity associated with cisplatin chemotherapy is well established, but opinion is split regarding the relative risk associated with preexisting hearing loss. The emerging consensus is that pretreatment loss does not increase the risk of cisplatin ototoxicity. Results from a preliminary study of a small sample from our patient population supports this consensus.
Durrant
J D
JD
Department of Otolaryngology, University of Pittsburgh, PA.
Rodgers
G
G
Myers
E N
EN
Johnson
J T
JT
D001299:Audiometry; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000150:complications / Q000188:drug therapy*; D006309:Hearing / Q000187:drug effects*; D006311:Hearing Disorders / Q000139:chemically induced*; D006801:Humans; D012307:Risk Factors
D002945:Cisplatin